Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea (MET-OSA)

NCT04530747 PHASE1, PHASE2 TERMINATED Results posted

The purpose of the study is to see if metformin improves metabolism in patients with obstructive sleep apnea (OSA) using positive airway pressure (PAP) therapy. Metformin is approved by the Food and Drug Administration (FDA) for the treatment and prevention of diabetes. It is not approved for use in patients with OSA.

Details

Lead sponsor	Pennington Biomedical Research Center
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	16
Start date	Thu Jan 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Sleep Apnea, Obstructive

Interventions

• Metformin + PAP
• Placebo oral capsule + PAP

Countries

United States